Ion Mobility-Enhanced Liquid Chromatography Coupled with Mass Spectrometry (LC-MS) Enables Reliable Detection of OXA-48-Like Carbapenemases Beyond Conventional Activity-Based Assays

This study demonstrates that liquid chromatography-mass spectrometry coupled with trapped ion mobility spectrometry (LC-MS timsTOF) enables rapid, sensitive, and specific functional detection and class-level differentiation of five clinically relevant carbapenemases, including OXA-48-like enzymes, by utilizing collisional cross-section measurements to identify a unique meropenem-derived marker that overcomes the limitations of conventional activity-based assays.

The Gist

The Problem: The "Ghost" Superbug

Imagine you are a detective trying to catch a group of criminals (bacteria) that have learned to break the police's best weapons (antibiotics called carbapenems). These criminals carry special tools called enzymes (specifically carbapenemases) that act like molecular scissors, snipping the antibiotic in half so it can't kill the bacteria.

There are different "gangs" of these criminals, named after their tools: KPC, NDM, VIM, IMP, and OXA-48.

For a long time, doctors have had a standard test to see if a bacteria is a criminal. It's like a "smoke test": you give the bacteria an antibiotic and see if the antibiotic disappears (gets destroyed).

• The Problem: The OXA-48 gang is tricky. When they cut the antibiotic, they don't just break it into pieces; they turn it into a completely different shape that looks exactly like the original weapon to our old detectors.
• The Result: The old tests say, "Nothing happened! The antibiotic is still there!" This is a false negative. The doctor thinks the bacteria is harmless, but it's actually a superbug that will kill the patient.

The New Solution: The "Shape-Shifter" Detector

This paper introduces a new, high-tech detective tool called LC-MS with Ion Mobility (specifically a machine called a timsTOF).

Think of the old test as just weighing the evidence. If the weight is the same, the old test assumes it's the same object.
The new machine adds a second dimension: Shape.

Here is how it works, step-by-step:

1. The Setup: The "Molecular Gym"

The scientists take the bacteria and feed them a specific antibiotic (Meropenem).

• Normal Criminals (KPC, NDM, etc.): They chew the antibiotic up. It gets messy and changes weight. Easy to spot.
• The Tricky Criminal (OXA-48): They don't just chew it; they twist it into a ring shape (a β-lactone).
  • The Twist: This new ring shape weighs exactly the same as the original antibiotic.
  • The Old Test: "Same weight? Must be the original antibiotic. No crime detected." (False Negative).
  • The New Test: "Wait a minute. Even though the weight is the same, the shape is different!"

2. The Magic Trick: The "Ion Mobility" Air Tunnel

This is the cool part. The new machine shoots these molecules through a tube filled with gas (an "air tunnel").

• Imagine throwing a flat sheet of paper and a crumpled ball of paper through a windy hallway. Even if they weigh the same, the flat sheet will get pushed around differently than the ball.
• In the machine, the "flat" original antibiotic and the "twisted" ring product bump into gas molecules at different rates. This measurement is called the Collisional Cross-Section (CCS).
• The machine measures this "wind resistance." It sees that the OXA-48 product has a different "wind resistance" than the original antibiotic.
• The Verdict: "Aha! You changed shape! You are definitely the OXA-48 criminal!"

Why This Matters

1. No More Missed Suspects: The old tests missed the OXA-48 gang about 20% of the time. This new method catches them 100% of the time because it looks at the shape, not just the weight.
2. One Test to Rule Them All: Instead of running three different tests to guess which gang is present, this single machine can look at the "debris" left behind and tell you which specific gang (KPC, NDM, or OXA-48) is in the room.
3. Speed: The whole process takes about 7 minutes per sample. That's fast enough to be used in a real hospital to help doctors choose the right medicine immediately.

The Bottom Line

Imagine you are trying to identify a suspect in a lineup.

• Old Method: You only check their height. If two suspects are the same height, you can't tell them apart.
• New Method: You check their height AND their shoe size (or how they walk). Even if they are the same height, their "walk" (shape) gives them away.

This paper proves that by adding this "shape-checking" technology to standard lab equipment, we can finally catch the sneaky OXA-48 superbugs that have been slipping through the cracks, ensuring patients get the right treatment faster.

Technical Summary

1. Problem Statement

Carbapenemases are enzymes that degrade carbapenem antibiotics, posing a critical threat to the treatment of multidrug-resistant Gram-negative bacterial infections. Accurate detection and classification of these enzymes (specifically distinguishing between Class A, B, and D) are vital for epidemiological surveillance and guiding targeted therapy with novel inhibitors.

Current diagnostic limitations include:

• False Negatives in OXA-48-like Enzymes: Conventional activity-based assays (e.g., Carba NP test, MALDI-TOF MS hydrolysis assays) rely on detecting mass shifts or pH changes caused by $\beta$-lactam ring hydrolysis. However, OXA-48-like enzymes (Class D) can degrade meropenem via an alternative pathway that forms a $\beta$-lactone product. This reaction does not result in a measurable mass change or pH shift, leading to false-negative results in standard assays.
• Lack of Class-Level Resolution: Many functional assays can detect carbapenemase activity but cannot differentiate between specific enzyme classes (e.g., KPC vs. NDM vs. OXA-48) without additional molecular testing.
• Target Limitations: Molecular methods are limited to predefined genetic targets and cannot detect novel or uncharacterized variants.

2. Methodology

The study developed and validated a functional detection assay using Liquid Chromatography coupled with Trapped Ion Mobility Spectrometry–Time-of-Flight Mass Spectrometry (LC–MS (timsTOF)).

• Sample Cohort: 55 clinical isolates were analyzed, including:
  • 17 OXA-48-like producers (alone).
  • 13 co-producers (OXA-48-like + NDM).
  • 9 NDM-only producers.
  • 6 KPC producers.
  • 5 VIM producers and 1 IMP producer.
  • 4 carbapenem-susceptible ESBL-producing controls.
• Experimental Workflow:
  1. Incubation: Bacterial suspensions were incubated for 2 hours with three carbapenem substrates: meropenem, imipenem, and ertapenem.
  2. Chromatography: Separation was performed on a C18 reversed-phase column using a 7-minute gradient elution.
  3. Mass Spectrometry: Analysis was conducted on a Bruker timsTOF Pro 2 system.
     • Dimensions: The method utilized three orthogonal dimensions for identification:
       1. Retention Time (RT): Chromatographic separation.
       2. Accurate Mass: High-resolution mass detection ($m/z$).
       3. Ion Mobility (IM): Separation based on the Collisional Cross-Section (CCS), which reflects the ion's size and shape in the gas phase.
• Data Analysis: Multivariate statistical analysis (PCA and PLS-DA) was used to cluster isolates based on their hydrolysis profiles.

3. Key Contributions & Technical Innovations

• Ion Mobility for Isomer Differentiation: The primary innovation is the use of CCS to distinguish between intact meropenem and the OXA-48-specific $\beta$-lactone product.
  • Both species have the same accurate mass ($m/z$ 384.16) and nearly identical retention times (difference of only 0.10 min).
  • However, they possess distinct CCS values: 192 Ų for intact meropenem vs. 186 Ų for the $\beta$-lactone.
  • This allows for the unambiguous detection of OXA-48 activity even when mass and retention time fail to differentiate the species.
• Single-Workflow Class Differentiation: The method enables the simultaneous detection of activity and differentiation of five clinically relevant carbapenemase classes (KPC, NDM, VIM, IMP, OXA-48-like) without the need for specific inhibitors or genetic sequencing.
• Substrate Specificity Validation: The study confirmed that meropenem is the superior substrate for detecting OXA-48-like enzymes (due to $\beta$-lactone formation), whereas imipenem and ertapenem did not yield comparable discrimination for this specific class.

4. Key Results

• OXA-48 Detection: The $\beta$-lactone marker was detected in 100% of OXA-48-like producing isolates (including co-producers) and was absent in all other groups (NDM, KPC, VIM, IMP, and ESBL controls). This demonstrated 100% sensitivity and specificity for OXA-48-like activity within the cohort.
• Class Differentiation:
  • OXA-48-like: Clearly separated from other groups in PCA/PLS-DA plots, driven primarily by the presence of the $\beta$-lactone product.
  • KPC vs. NDM: These groups showed overlapping hydrolysis profiles (complete ring opening of all substrates) and were difficult to distinguish solely by LC-MS degradation patterns, though partial separation was observed in multivariate models.
  • VIM/IMP: VIM producers (all P. aeruginosa) clustered distinctly, partly due to enzyme activity and partly due to organism-specific metabolites (e.g., pyochelin, PQS precursors).
• Control Specificity: ESBL-producing controls showed variable degradation of imipenem (highlighting imipenem's susceptibility to non-carbapenemase hydrolysis) but remained stable with meropenem and ertapenem, reinforcing meropenem as the preferred substrate.
• Throughput: The total analysis time was 7 minutes per sample following a 2-hour incubation, making it compatible with high-throughput clinical workflows.

5. Significance and Implications

• Solving the OXA-48 Diagnostic Gap: This study provides a robust solution to the long-standing problem of false negatives in OXA-48 detection by leveraging ion mobility to detect structural isomers that mass spectrometry alone cannot resolve.
• Functional Genomics: The approach detects enzymatic function rather than genetic presence, allowing for the identification of novel or mutated variants that might escape PCR-based detection.
• Clinical Feasibility: With the increasing availability of high-resolution LC-MS systems in clinical laboratories (often used for therapeutic drug monitoring), this method offers a pathway to integrate advanced carbapenemase diagnostics into routine microbiology without requiring specialized molecular reagents.
• Future Directions: While highly effective for OXA-48, the study notes that distinguishing between Class A (KPC) and Class B (NDM) enzymes purely by hydrolysis profiles remains challenging and may require complementary methods. Future work will focus on expanding validation to larger, multicenter cohorts.